文献速递造血干细胞移植与细胞治疗淋巴瘤白血病

从统计学视角总结美国食品药品监督管理局对嵌合抗原受体(CAR)T细胞生物制品许可申请的批准

Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective.
PubMed 文献 · J Clin Oncol · 2022-05-25

本文从统计学视角总结美国食品药品监督管理局(FDA)已批准的五个自体CAR T细胞产品(七个适应症),阐述其需为每位患者单独制造的特点对研究设计、统计分析和结果解读的影响,并分享统计审评经验及对CAR T细胞试验设计与统计分析的考虑,同时描述新采用的估计目标框架如何帮助澄清试验设计中的细微问题。

要点

  • 自2017年tisagenlecleucel和axicabtagene ciloleucel获批以来,FDA已批准五个自体CAR T细胞产品用于七个适应症。
  • 自体CAR T细胞产品需为每位患者单独制造,这一特点对研究设计、统计分析和结果解读均有影响。
  • 本文分享CAR T细胞产品统计审评经验,并提供试验设计与统计分析的考虑,包括估计目标框架的应用。

核心结论

  • 自体CAR T细胞产品需为每位患者单独制造的特点对研究设计、统计分析和结果解读均有影响,本文分享了统计审评经验并提供相关考虑。

研究设计与样本

  • 本文为FDA统计审评经验的总结性文章,涉及截至发文时FDA已批准的五个自体CAR T细胞产品、七个适应症。

主要发现

  • 2017年tisagenlecleucel和axicabtagene ciloleucel获批标志着肿瘤治疗发展的里程碑。
  • 自2017年以来,以CAR T细胞为代表的新型癌症治疗在既往难治疾病的治疗甚至治愈方面持续取得突破。
  • 截至发文时,FDA已批准五个自体CAR T细胞产品用于七个适应症。
  • 自体CAR T细胞产品需为每位患者单独制造,这一特点有别于传统肿瘤药物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The approval of tisagenlecleucel and axicabtagene ciloleucel in 2017 marked a milestone in the development of oncology therapies. Since 2017, the breakthrough in treatment or even cure of previously intractable diseases represented by this new class of cancer treatments has continued with subsequent chimeric antigen receptor T (CAR T)-cell approvals. To date, the US Food and Drug Administration has approved five autologous CAR T-cell products for seven indications. A feature of autologous CAR T-cell products that differentiates them from traditional oncology drugs is that they need to be manufactured specifically for each patient. This feature has implications in study design, statistical analyses, and interpretation of study results. In this article, we share our experiences in the statistical review of CAR T-cell products and provide considerations for the design and statistical analyses of CAR T-cell trials. We also describe how the newly adopted estimand framework for clinical trials can help clarify nuanced issues in CAR T-cell trial design.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lin X, Lee S, Sharma P, et al. Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective. J Clin Oncol. 2022. PMID: 35613410. doi:10.1200/JCO.21.02558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。